Introduction
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease globally, affecting adults 65 and older [
1]. With an aging population, the disability-adjusted life years for PD more than doubled globally between 1990 and 2016 [
2]. As PD progresses, complications such as non-motor symptoms and gait problems increase [
3], significantly affecting the patient’s quality of life [
4]. It is estimated that the direct medical cost for PD is approximately $14.2 billion in the US, with $4.8 billion attributed to loss of income [
5]. In China, it is estimated that there will be approximately five million patients with PD by 2030, accounting for almost 50% of the global PD population [
6]. Meanwhile, drug costs accounted for 97.82% of outpatient medical expenditures [
7]. To alleviate the economic burden on families with PD patients, PD has been included in major disease insurance in the Chinese government insurance system since 2007 [
8].
Antiparkinsonian medication is an essential therapeutic strategy for patients with PD [
9,
10]. Poor adherence to antiparkinsonian drugs (APDs) may not only reduce patients’ quality of life but also predispose them to complications associated with PD, thereby increasing mortality risk [
11,
12]. Adequate APD adherence, however, can alleviate PD symptoms and motor complications, improve quality of life [
13], and decrease all-cause healthcare costs by reducing ambulatory visits, admissions, and lengths of stay [
14‐
16]. A recent review indicated that achieving target medication adherence would save €239,000–€576,000 in Germany and €917,000–€2,980,000 in the UK for every 1,000 patients over 1.5 years, respectively [
17].
Previous studies on APD adherence have considered demographic and social factors (e.g., age, marital status, educational level, and income), as well as clinic-related factors, such as motor and non-motor symptoms, primarily cognitive and mood symptoms, disease duration, and regimen complexity [
14,
18]. However, when evaluating the clinical factors that affect adherence to PD treatment, the literature has only focused on specific diseases within a single system, such as depression [
16,
19] and gastrointestinal diseases [
16]. However, managing the care and medications of patients is complex and requires multidisciplinary clinical expertise [
20]. To improve patient benefits, a systematic approach is warranted to understand the effect of multiple comorbidities, including other neurological diseases and systems.
To the best of our knowledge, no international comparative data are available on the medical costs for Chinese patients with PD [
7,
21]. Most studies have been based on survey data, which have limited accuracy with regard to cost estimates [
7]. Using electronic medical records in a tertiary hospital in China, the present study reports medication adherence and medical costs for patients with PD. The two measures for assessing medication adherence were ascertained: medication possession ratio (MPR) and proportion of days covered (PDC). They focused on clinical factors that comprehensively included PD-related neurological diseases and disorders of other systems to systematically understand barriers to patient adherence to medication in real-world practice. Subsequently, the additional direct medical costs that are associated with medication adherence were estimated.
Discussion
Electronic medical records of Chinese patients with PD demonstrated moderate medication adherence. Older age, concurrent digestive system diseases, and epilepsy were factors associated with poorer APD adherence, whereas an increased number of APDs or all medications, and higher daily LED resulted in improved adherence. The average annual total medical costs per patient were less than one-tenth the costs for patients with PD in developed countries. Higher APD adherence rates are associated with higher direct medical costs and older age is associated with increased medication expenses.
The results showed that comorbid epilepsy leads to poor medication adherence for patients with PD. In the cohort in the present study, the proportion of patients with PD with epilepsy at baseline was low (3.4%), corroborating data from other countries [
28]. Epilepsy and dementia are comorbidities of PD, both of which increase the risk of cognitive impairment in patients [
29,
30]. However, in the present study, when the two comorbidities were combined into a single variable, medication adherence was no longer affected. Moreover, the effect of epilepsy remained significant even after adjusting for patient age and other potential confounding factors. Prior research has demonstrated poor adherence to antiepileptic medication among patients with epilepsy [
31]. Therefore, epilepsy may be a significant barrier to medication adherence in patients with PD. To the best of our knowledge, this is the first report of its kind within a real-world clinical setting. Consequently, further studies are required to establish definitive causal relationships. Clinicians and pharmacists should pay greater attention to patients with comorbid epilepsy during baseline assessment, as this factor can impact medication adherence, despite the relatively low prevalence of epilepsy among patients with PD.
The results of the present study indicated a negative association between age and medication adherence, which corroborates the results of prior research [
19]. The results also demonstrated that concurrent digestive system diseases resulted in lower adherence rates to medication, similar to the findings of an earlier study [
16]. In the present study, 20.9% of the patients with PD who had concurrent digestive system diseases at baseline had constipation and other types of esophagus/stomach/duodenum diseases. Constipation is a common adverse reaction of APDs [
32], cited as the primary cause for the discontinuation of APDs by many patients [
18]. Wallen et al. [
33] proposed hypotheses regarding the role of the gut microbiome in PD pathogenesis, including the incomplete penetrance of PD susceptibility genes and potential triggers of pathology related to gut penetrance [
33]. The findings, which highlight the factors responsible for reduced medication adherence, imply that patients with PD and comorbid digestive disorders may experience exacerbated symptoms after using APDs. In addition, the presence of comorbid digestive diseases in patients with PD was significantly associated with older age in the present study (Kolmogorov–Smirnov test,
p < 0.001), emphasizing the importance of collaboration among gerontologists, gastroenterologists, and neurologists in the management of PD.
In the present study, the average annual total medical cost per patient with PD in China was estimated as $1,604.56, which was much lower than that of the patients with PD in the US ($23,041) and Sweden (€15,958) [
34,
35]. The lower costs in China can be explained partially by low medication adherence rates. The cost of APDs in China is lower than in developed countries. The ratio of the median APD cost in China to that in the US, Australia, India, Canada, and the UK is 0.51 [
36]. Especially after the Zero Markup Drug Policy for Public Hospitals was implemented in Beijing on April 1, 2017, the price of most APDs dropped [
7], and the cost of managing PD has decreased [
37].
Finally, the findings revealed that higher adherence to APDs is associated with the use of a larger number of medications and increased healthcare expenses, which is inconsistent with previous research findings [
38]. Patients who use a variety of APDs or higher daily LED are often those who experience more severe PD symptoms and consequently adhere more closely to their physicians’ recommendations. Increased awareness of PD treatment may improve medication adherence [
19]. Therefore, to improve medication adherence, patients with mild symptoms should also be considered when providing follow-up care, patient education, and other interventions. The fragmentation of China’s healthcare system can also explain such discrepant findings between the present study and prior research. Inherent in the Soviet model and the barefoot doctor movement [
39], specialists in China are primarily concentrated in tertiary hospitals, and general practitioners are not well trained and lack capacity. Consequently, patients with PD are urged to seek treatment at tertiary hospitals to access initial or more effective medication regimens. In such hospitals, physicians often have no time or incentive to provide effective guidance. Moreover, they may not be aware of the medication status and associated costs for patients receiving care in other hospitals or regions. Data from the present study were collected from Peking University Third Hospital, which is a referral hospital located in Beijing, China. Patients without medical insurance in Beijing (34.9%) self-transferred to other provinces. For such reasons, policymakers should minimize regional differences in medical capacity to prevent patients from seeking healthcare across regions, and in turn, improve medication adherence.
The present study had several strengths. It was the first attempt to assess adherence to various types of APDs among Chinese patients with PD comprehensively. The authors attempted to include all potential comorbidities. To the best of our knowledge, this is the first report that considers epilepsy as a factor that is associated with poor APD medication adherence. The present study used electronic medical records of the patients treated at a 2,264-bed tertiary care medical center and teaching institution in Beijing. The records contained data from 3.94 to 4.22 million outpatient visits and 100,549–137,655 admissions, respectively, during the study period. China is one of the most rapidly aging countries globally; therefore, the present study on medication adherence for PD, conducted at a top tertiary hospital in the capital of China, not only has guiding significance for healthcare providers and policymakers in China but also has reference value for international peers.
The present study had some limitations. The data used covered only one medical center in Beijing, China, and the data collection period was only 32.5 months. The former may be the reason for the low inpatient admission rate of patients with PD during the study period and could explain the fact that out of 2,640 patients with PD diagnosis, only 1,712 patients were prescribed APDs more than twice. Electronic health records-pharmacy-linked data will facilitate a better generation of real-world evidence to more reliably evaluate APD medication adherence in future studies [
40,
41]. The present study could not comprehensively present the medication status of patients with PD due to geographical and time limitations. Information regarding the stages of PD was not included in the data; therefore, the relationship between PD stages and medication adherence could not be evaluated. The data used in the present study only contained “prescribed use” information (APD filled data), without “actual use” information [
42,
43], and did not contain the daily dosage of the prescription. Therefore, the supplied days of a single prescription could not be obtained by dividing the total dosage of the prescription by the daily dosage. Consequently, the calculations of the MPR, PDC, and daily LED were imprecise. Furthermore, APD data during hospitalization were not included because of the small size of inpatient admission data (Table
S4), and gamma regression analysis was performed for APD costs, non-APD costs, and other outpatient costs. The impact of APD adherence on other costs (such as non-medical and invisible costs) and the economic burden on patients with PD requires further research. The second part of the sensitivity analysis (Fig.
S5) indicated a trend of decreasing adherence with the extension of the follow-up time, which suggests that further studies on the changing regularity of medication adherence with an increase in PD treatment time can be significant and pioneering. This needs to be supported by longer follow-up data. The data do not provide information on patients’ income, marriage, and complexity of posology, which may affect PD patients’ adherence [
18]. In addition, the Peking University Third Hospital introduced a collaborative pharmaceutical care service program in March 2017. Clinical pharmacists were engaged in the care of patients with PD, provided advice on how to use each medicine, and offered personalized explanations on request. Since doctors were not engaged in the interactions, the program may not affect patient diagnoses in the electronic medical records. However, the engagement of pharmacists may improve patients’ adherence [
7]. Only 170 samples were available before the program, and there was a lack of adequate power (< 200) to detect the effect of the program. Future work is warranted to assess whether and how engaging clinical pharmacists in the care process could affect patients’ adherence, particularly for PD patients who used to have comorbidities.
Overall, the present study was a retrospective data analysis, which attempted to identify certain inferences related to medication adherence and aimed to guide future research. In future research, a structured approach (such as a framework based on timelines–events–objectives–sources) could be used [
42] and comprehensive data (such as multi-center data, electronic health records-pharmacy-linked data, and databases containing treatment effects and outcomes) could be adopted to explore adherence measures closer to the real status, to identify other factors affecting APD adherence, such as collaborative pharmaceutical care service, different APD treatment regimens, other concurrent diseases, PD treatment time, and factors contributing to better treatment effects.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.